21st Austria weekly - Marinomed Strabag Vienna Airport 13/04/2022 [pic1]Marinomed: Marinomed Biotech AG an Austrian science-based biotech company with globally marketed therapeutics today announced encouraging results for the 2021 financial year. The upfront payment from first Budesolv licensing agreement and strong demand Carragelose products helped Company to generate highest revenues in its history while operating result EBIT full year also improved considerably once again. ended a 43% increase 11.6 mn 2020: Euro 8.1 m. As planned research development spending rose by 26% 7.5 m 5.9 m majority of which was used clinical projects. loss period slightly -5.9 -6.0 mn. is aiming take innovative approaches next level create sustainable value patients public healthcare systems stakeholders. will work hard 2022 further expand business efforts line 2025 strategy develop protocols advance work.Marinomed Biotech: performance: -2.46% Strabag: Management